Allianz Asset Management GmbH Trims Stake in United Therapeutics Corporation $UTHR

Allianz Asset Management GmbH lowered its position in United Therapeutics Corporation (NASDAQ:UTHR) by 29.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,072 shares of the biotechnology company’s stock after selling 19,018 shares during the period. Allianz Asset Management GmbH owned approximately 0.10% of United Therapeutics worth $18,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new position in United Therapeutics during the 2nd quarter valued at $136,453,000. Invesco Ltd. lifted its position in shares of United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the period. Assetmark Inc. grew its holdings in shares of United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after purchasing an additional 197,384 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of United Therapeutics in the second quarter worth about $55,746,000. Institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $470.43, for a total transaction of $10,584,675.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders have sold 542,214 shares of company stock worth $260,031,533. Insiders own 10.30% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR stock opened at $485.36 on Friday. The company has a market cap of $20.90 billion, a P/E ratio of 18.39, a PEG ratio of 2.55 and a beta of 0.85. The stock’s 50-day moving average is $486.75 and its 200 day moving average is $426.57. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on UTHR. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a report on Wednesday, October 29th. HC Wainwright lifted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Wells Fargo & Company lifted their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada increased their price target on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.